ngµç×ÓÓÎÏ·

05

¿ÆÑÐÏ£Íû

ҩѧԺ±Ï»ÝæÏ½ÌÊÚÍŶÓÕ¹ÏÖPPAR¦Áͨ¹ýYAP-TEADÐźÅÔö½ø¸ÎÔö´óºÍ¸ÎÔÙÉúµÄлúÖÆ

¸å¼þȪԴ£º£º£ºÒ©Ñ§Ôº ÔĶÁÁ¿£º£º£º

¸ÎÔàÒÆÖ²ºÍ²¿·Ö¸ÎÇгýÊÇÏÖÔÚÖÎÁƸΰ©¡¢¸ÎÓ²»¯µÈÖÕÄ©ÆÚ¸Î²¡Ê×Ñ¡µÄ×îÓÐÓÃÊֶΡ£¡£¡£¸ÎÔàÔÙÉúÄÜÁ¦ÊǸÎËðÉË¡¢²¿·Ö¸ÎÇгý¼°¸ÎÒÆÖ²ÊõºóÐÞ¸´ÓëÔ¤ºóµÄÒªº¦ £¬£¬£¬µ«µ÷¿Ø¸ÎÔÙÉúµÄÓÐÓðеãºÍ¸ÉÔ¤Ò©ÎïØÑ·¦¡£¡£¡£Òò´Ë £¬£¬£¬ÉîÈëÑо¿¸ÎÔÙÉúÆøÖÆÓëDZÔڰеãÓÐÖ÷ÒªÒâÒå¡£¡£¡£

2021Äê8ÔÂ13ÈÕ £¬£¬£¬ngµç×ÓÓÎϷҩѧԺ±Ï»ÝæÏ½ÌÊÚÍŶÓÔÚHepatologyÔÓÖ¾ÔÚÏß½ÒÏþÁËÌâΪ¡°YAP-TEAD mediates peroxisome proliferator-activated receptor ¦Á-induced hepatomegaly and liver regeneration in mice¡±µÄÑо¿ÂÛÎÄ¡£¡£¡£¸ÃÂÛÎÄз¢Ã÷¹ýÑõ»¯ÎïøÌåÔöÖ³ÎD»îÊÜÌå¦Á£¨peroxisome proliferator-activated receptor ¦Á, PPAR¦Á£©Í¨¹ý×÷ÓÃÓÚ¸ÎÔà¾ÞϸµÄ¿ØÖÆÆ÷ºÍÊàŦÐźšª¡ªyesÏà¹ØÂѰף¨yes-associated protein £¬£¬£¬YAP£© £¬£¬£¬Ôö½ø¸ÎÔö´óºÍ¸ÎÔÙÉúµÄй¦Ð§»úÖÆ £¬£¬£¬ÎªPPARa×÷ΪÔö½ø¸ÎÔÙÉúµÄDZÔڰеãÑо¿ÌṩÀíÂÛÒÀ¾ÝºÍÊý¾ÝÖ§³Ö £¬£¬£¬Îª¸ÎÔÙÉúDZÔڰеãµÄÑо¿ÌṩÐÂÊӽǡ£¡£¡£

¸ÃÑо¿ÔÚÒ°ÉúÐÍСÊ󡢸Îϸ°ûÌØÒìÐÔPpar¦ÁÇóý£¨Ppara¦¤Hep£©Ð¡Êó¼°²¿·Ö¸ÎÇгýСÊóÄ£×ÓÉÏÈ·Ö¤ÁËPPAR¦Á¾­µä¼¤¶¯¼ÁWY-14643Ôö½ø¸ÎÔàÔö´ó¼°ÔÙÉúµÄ×÷Óã» £»²¢ÔËÓÃÃâÒß×黯ÆÊÎöÕ¹ÏÖPPAR¦Á¼¤¶¯¿Éµ¼ÖÂСÊó¸ÎÔàÖÐÑë¾²ÂöÇø¸Îϸ°û±ä´óºÍÞ²ÂöÇø¸Îϸ°ûÔöÖ³¡£¡£¡£Í¬Ê± £¬£¬£¬Ó¦ÓÃÃâÒß¹²³ÁµíºÍ¹²¶¨Î»µÈÒªÁì֤ʵPPAR¦ÁÓëYAP¾ßÓÐDZÔÚµÄÏ໥×÷Óà £¬£¬£¬PPAR¦ÁµÄE domainÊÇPPAR¦ÁÓëYAPµÄÂѰ׻¥×÷µÄÒªº¦Á¬ÏµÇøÓò £¬£¬£¬PPAR¦Á¼¤¶¯¿ÉÔö½øYAPºËתλ £¬£¬£¬Éϵ÷YAPÏÂÓΰлùÒò¡£¡£¡£½øÒ»²½Ñо¿ÔÚ¸øÓèСÊóYAP-TEADÁ¬ÏµÒÖÖÆ¼ÁÎ¬Ìæ²´·Òºó·¢Ã÷YAPÓëTEADµÄÁ¬ÏµÔÚPPAR¦ÁËùÖ¸ÎÔö´óÖÐʩչÖ÷Òª×÷Óà £¬£¬£¬²¢ÔÚAAV-Yap shRNAСÊóºÍ¸ÎÌØÒìÐÔYapÇóý£¨Yap¦¤Hep£©Ð¡ÊóÄ£×ÓÉÏÈ·Ö¤PPAR¦ÁËùÖ¸ÎÔö´óÊÇYAPÒÀÀµÐԵġ£¡£¡£×ÛÉÏËùÊö £¬£¬£¬±¾Ñо¿Ö¤ÊµÁËPPAR¦Á¿Éͨ¹ýÓëYAPDZÔÚµÄÂѰ׻¥×÷¡¢Ôö½øYAPºËתλ¡¢Ó°ÏìYAPÓëTEADÁ¬Ïµ¡¢Éϵ÷YAPÏÂÓΰлùÒò £¬£¬£¬Ôö½ø¸Îϸ°ûÔö´óÓëÔöÖ³ £¬£¬£¬½ø¶øÔö½øÐ¡ÊóÐÄÀíÐÔ¸ÎÔö´ó¼°²¿·Ö¸ÎÇгýºó¸ÎÔÙÉú¡£¡£¡£±¾Ñо¿Ð·¢Ã÷PPAR¦Áͨ¹ýYAP-TEADÐźÅÔö½ø¸ÎÔö´óÓë¸ÎÔÙÉúµÄй¦Ð§»úÖÆ £¬£¬£¬ÎªPPAR¦ÁÔö½ø¸ÎÔö´óÓë¸ÎÔÙÉú×÷ÓÃÌṩп´·¨ £¬£¬£¬ÎªPPAR¦Á×÷Ϊ¸ÎÔÙÉúDZÔڰеãÌṩ¿ÆÑ§Ö¤¾Ý¡£¡£¡£

Ê×Ò³|ngµç×ÓÓÎÏ·Öйú¼¯ÍŹٷ½ÍøÕ¾

¸ÃÍŶÓÓÚ2019ÄêºÍ2021Äê»®·ÖÔÚHepatology ºÍActa Pharmaceutica Sinica B ÉÏÒÔ·âÃæÎÄÕÂÕ¹ÏÖÁËÁíÍâÁ½¸öºËÊÜÌ壨nuclear receptors £¬£¬£¬NRs£© £¬£¬£¬ÔÐÍéXÊÜÌ壨pregnane X receptor, PXR£©ºÍ×é³ÉÐÍÐÛçÞÍéÊÜÌå(constitutive androstane receptor, CAR) £¬£¬£¬Í¨¹ýYAPÐźÅͨ·Ôö½ø¸ÎÔö´óºÍ¸ÎÔÙÉúµÄй¦Ð§»úÖÆ¡£¡£¡£ÏÖÔÚ¹ØÓÚPPAR¦ÁµÄ×îÐÂÑо¿Ð§¹ûÊǸÿÎÌâ×éÔÚºËÊÜÌåÓëYAPµ÷¿Ø¸ÎÔö´óÓë¸ÎÔÙÉúÑо¿ÁìÓòµÄÓÖÒ»Á¦×÷¡£¡£¡£

ngµç×ÓÓÎϷҩѧԺ²©Ê¿Ñо¿Éú·¶Ê˳ɺ͸ßÔÃΪ±¾ÂÛÎĵĵÚÒ»×÷Õß £¬£¬£¬±Ï»ÝæÏ½ÌÊÚΪÂÛÎĵÄͨѶ×÷Õß¡£¡£¡£ÉÏÊöÑо¿ÊÂÇé»ñµÃ¹ú¼Ò×ÔÈ»¿ÆÑ§»ù½ðί½ÜÇà¼°ÃæÉÏÏîÄ¿¡¢¹ú¼ÒÖØµãÑз¢ÍýÏëÖØµãרÏîµÈ¶àÏî»ù½ðµÄ×ÊÖú¡£¡£¡£

ÂÛÎÄÁ´½Ó£º£º£ºhttps://aasldpubs.onlinelibrary.wiley.com/doi/10.1002/hep.32105

¡¾ÍøÕ¾µØÍ¼¡¿